ARAadia Rana

Aadia Rana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aadia Rana has a total of 309 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Operational Lessons From Implementing Public Health Data–Based Recruitment and Home STI Screening to Enroll a Cohort of Women Vulnerable to HIV in Alabama

    by Jiaying Hao, Desiree Phillips, Madeline C Pratt, Nuvan Rathnayaka, Kara Bennett, Anthony Merriweather, Lisa Hightow-Weidman, Henna Budhwani, Kathleen Hurwitz, Aadia I Rana, et al.

    The Camellia Cohort enrolls women with recent (past 90 days) gonorrhea or syphilis reported to the Alabama State Health Department. Eligible women are contacted to complete consenting procedures and home-based STI/HIV screening. Recruitment processes and strategies are refined based on interim findings, then modified to optimize recruitment yield.

  • Anxiety Among Perinatal Women Living With HIV: A Global Scoping Review

    by Meghan C. Jones, Jun Y. Byun, Ikenna Obasi Odii, Rebecca Billings, Aadia I. Rana, Frank Puga, Christina Psaros, Liang Shan, Zenoria Causey Pruitt, Allison Shorten, et al.

    Anxiety symptoms and disorders among perinatal women living with HIV (WLHIV) represent an important area for research and clinical intervention. Guided by the Arksey and O'Malley methodological framework, this scoping review highlights the scarcity of studies addressing anxiety among perinatal WLHIV. Results indicate that anxiety as a distinct concept is not well-defined. Inconsistencies in defining anxiety during the perinatal period contribute to variances in the measures used across studies, estimates of anxiety prevalence, and implications for treatment and intervention. Longitudinal research examining the relationship between anxiety and associated contextual factors over time and during different stages and transitions is needed to improve anxiety symptom and disorder identification, treatment, and intervention for perinatal WLHIV.

  • Open Access

    Syphilis Infections Among Women of Reproductive Age in the Southern United States: An Analysis From the Study of Treatment and Reproductive Outcomes (STAR)

    by Madison Sophia Meyer, Erin Rebecca Carr, Candice A Sternberg, Paola B Fernandez, Laura Beauchamps, Patricia Raccamarich, JoNell Potter, Daniel Westreich, Seble Kassaye, Elizabeth F Topper, et al.

    Syphilis is resurging among reproductive-age women in the United States. Among 773 women with and without HIV enrolled in the Study of Treatment and Reproductive Outcomes (STAR), 2.9% had prior/current syphilis, including 1 pregnant participant. Factors associated with prior/current syphilis included lower education, unemployment, incarceration history, and history of transactional sex.

  • Top Cited Papers
    Open Access

    Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges

    by Aadia I. Rana, Lu Zheng, Jose Castillo-Mancilla, Yajing Bao, Sara Sieczkarski, Kristina M. Brooks, Jordan E. Lake, Carl Fichtenbaum, Sonya L. Heath, Pablo F. Belaunzaran-Zamudio, et al.

    Randomized trials of long-acting injectable antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) who face challenges with adherence to oral medication are lacking. We conducted an open-label, randomized trial involving persons with HIV who had inadequate adherence to ART (a persistent HIV-1 RNA level of >200 copies per milliliter or loss to follow-up). Participants received up to 24 weeks of adherence support, conditional economic incentives, and standard care with oral ART (step 1). Participants who had an HIV-1 RNA level of 200 copies per milliliter or lower in step 1 were randomly assigned in a 1:1 ratio to either continue standard care or switch to monthly injections of long-acting cabotegravir plus rilpivirine with or without oral lead-in therapy (step 2). The primary outcome was regimen failure, defined as confirmed virologic failure (two consecutive HIV-1 RNA measurements of >200 copies per milliliter) or treatment discontinuation during step 2. In step 1 of the trial, we enrolled 453 participants; the median age was 40 years, 63% were Black, and 29% had been assigned female sex at birth. In step 2, a total of 306 participants underwent randomization; 152 were assigned to receive cabotegravir-rilpivirine and 154 to receive standard care. Step 2 randomization was stopped early on the basis of the superiority of cabotegravir-rilpivirine to standard care in secondary outcomes at a prespecified analysis performed after a median follow-up of 48 weeks. The cumulative incidence of regimen failure by week 48 was 22.8% in the cabotegravir-rilpivirine group and 41.2% in the standard-care group (difference, -18.4 percentage points; 98.4% confidence interval [CI], -32.4 to -4.3; P = 0.002). The cumulative incidence of an adverse event was 43.5% in the cabotegravir-rilpivirine group and 42.4% in the standard-care group (difference, 1.1 percentage points; 95% CI, -12.7 to 15.0). Resistance-associated mutations developed in 2 participants with confirmed virologic failure in each group. Monthly injections of long-acting cabotegravir-rilpivirine were superior to standard oral ART in reducing the risk of regimen failure among persons with HIV who had adherence challenges. (Funded by the National Institute of Allergy and Infectious Diseases; LATITUDE ClinicalTrials.gov number, NCT03635788.).


  • Open Access

    Reduced Adherence to Antiretroviral Therapy in Pregnant Women With HIV With Intimate Partner Violence in the United States

    by Aasith Villavicencio, John B Jemmott, Fatemeh Ghadimi, Hervette Nkwihoreze, Sara Seyedroudbari, William R Short, Aadia Rana, Anandi N Sheth, Rachel K Scott, Gweneth B Lazenby, et al.

    Background: Despite increased access to antiretroviral therapy (ART) for women with HIV (WWH), poor postpartum HIV care retention persists. This analysis evaluates Intimate Partner Violence (IPV) and ART adherence in pregnant WWH. Methods: We analyzed secondary data from a US behavioral intervention trial to improve postpartum retention in WWH. Data were collected from the baseline survey including the Edinburgh Postnatal Depression Scale (EPDS), adverse childhood experiences (ACE), and HIV-related stigma scores, and the WHO Violence Against Women questionnaire to assess IPV. A multivariable logistic regression examined associations between IPV timing (before, during pregnancy, any) and type (physical, psychological, sexual) and ART adherence (≥80% ART doses in the prior month). Results: A total of 137 pregnant WWH enrolled between March 2020 and March 2024 were included: mean age was 30.5 (SD 5.6); 83% were Black, 14% Hispanic; mean number of pregnancies was 3.3 (SD 2.1). Depression, stigma, and ACEs were prevalent: EPDS scores of ≥10 were seen in 45% of women, ≥4 ACEs in 23%, and 51% reported HIV-related shame. Forty women (29%) reported IPV exposure. Higher EPDS, ACE, and stigma scores were seen in women exposed to IPV (P < .02). Physical IPV during pregnancy had the strongest association with decreased ART adherence in pregnancy (adjusted odds ratio = 0.10, P = .02). Psychological IPV and any IPV type during or before pregnancy were also associated with lower odds of adherence. Conclusions: We found high IPV rates and a significant negative association with ART adherence among pregnant WWH highlighting the importance of addressing IPV in HIV care.

  • Open Access

    Long-Acting Antiretroviral Therapy for Breastfeeding Women With HIV Experiencing Barriers to Adherence in Zimbabwe: Modeling Clinical Impact and Cost-effectiveness

    by Sujata E Tewari, Risa Hoffman, Shahin Lockman, Clare F Flanagan, Karen A Webb, Stephanie Horsfall, Anesu Chimwaza, Caitlin M Dugdale, Judith Currier, Efison Dhodho, et al.

    Background: Long-acting antiretroviral therapy (LA-ART) may reduce adherence barriers for postpartum women with HIV (PPWH), reducing vertical transmission (VT) and improving pediatric life expectancy (pLE), but efficacy and drug costs are uncertain. Methods: Using a microsimulation model, we simulated mother-infant dyads for two cohorts of PPWH engaged in care, receiving oral tenofovir/lamivudine/dolutegravir (TLD) in pregnancy, and facing adherence challenges in Zimbabwe: mothers without (NVS) and with (VS) viral suppression at delivery. We modeled two post-delivery strategies: standard of care (SOC: TLD continuation) or LA-ART (switching to LA-cabotegravir/rilpivirine [CAB/RPV]). Key inputs included: 6-month-postpartum viral suppression (LA-ART: NVS = 85%/VS = 90%; SOC: NVS = 63%/VS = 78%), ART costs/year (CAB/RPV=$144/TLD=$43.20), and VT risk (0.06%–0.89%/month, range by maternal RNA). Outcomes include VT, pLE, costs (maternal ART in breastfeeding plus pediatric HIV-related lifetime care), and incremental cost-effectiveness ratios (ICERs, $/year-of-life-saved [YLS]; cost-effective: ICER≤$800/YLS [0.5× Zimbabwe GDP]. Results: LA-ART would reduce VT compared with SOC (NVS: from 7.49% to 6.58%/VS: from 4.17% to 3.80%), averting ∼160 infections/year in Zimbabwe. For NVS, LA-ART would improve pLE (SOC = 66.08y, LA-ART = 66.40y) at nearly equal cost (SOC = $764/child, LA-ART = $763/child); LA-ART would not be cost-effective if CAB/RPV cost >$228/year or 6-month suppression were <74%. For VS, LA-ART would lead to higher pLE and costs (67.52y, $555/child) than SOC (67.40y, $445/child), with ICER=$2449/YLS; LA-ART would become cost-effective if CAB/RPV cost ≤$84/year. Conclusions: LA-ART for breastfeeding women experiencing adherence challenges could reduce infant infections. If efficacies and costs are confirmed, LA-ART for NVS women would improve outcomes and be minimally cost-saving; for VS women, LA-ART would be cost-effective in Zimbabwe at costs ≤$84/year.


  • Oral health–related quality of life among reproductive-aged women with HIV in the southern United States

    by Carrigan Parish, Yue Pan, Yawen Lu, Apoena Ribeiro, Catalina Ramirez, Nicholas Fonseca Nogueira, Deborah L. Jones, Patricia Del Carmen Raccamarich, Elizabeth F. Topper, Daniel Westreich, et al.

  • Open Access

    Substance Use and Drug Treatment Among Reproductive-Age Women With and Without HIV in the Southern United States

    by Ayako Wendy Fujita, C Christina Mehta, Qian Yang, Tina T Tisdale, Maria L Alcaide, Aadia Rana, Deborah J Konkle-Parker, Daniel Westreich, Seble G Kassaye, Elizabeth F Topper, et al.

    Background: Women with human immunodeficiency virus (HIV; WWH) and with substance use (SU) have poorer HIV-related outcomes. We characterized SU and treatment across reproductive life stages among Study of Treatment And Reproductive Outcomes (STAR) participants. Methods: The STAR is a prospective cohort of WWH and women without HIV (WWoH) across 6 Southern US sites. We analyzed baseline participant data (2021–2024) on self-reported past-year SU (nonmedical drug use, hazardous alcohol use, tobacco use, and nonmedical cannabis use), as well as drug and alcohol use treatment. We assessed SU and treatment by HIV and pregnancy status. Results: Among 891 women (526 WWH and 362 WWoH), 12% (9% of WWH and 15% WWoH; P = .02) reported past-year drug use; 15%, hazardous alcohol use (11% and 20%, respectively; P < .001); 37%, tobacco use (34% and 41%; P = .10); and 45%, cannabis use (40% and 52%; P = .001). The most frequently used drug was crack/cocaine (61%). Among pregnant women, 7% reported past-year drug use, 12% hazardous alcohol use, 28% tobacco use, and 39% cannabis use. Among women with past-year drug use (n = 102), 16% reported experiencing accidental overdose, and 23% had used any drug treatment program in the past year. There was no statistically significant difference in drug treatment by HIV or pregnancy status. Conclusions: Among reproductive-age WWH and WWoH in the Southern United States, SU was common, predominantly stimulant use with high rates of co-occurring cannabis and tobacco use. Implementation studies are needed to understand barriers and facilitators to integrating SU disorder care into HIV settings tailored to the needs of reproductive-age women.


  • Impact of a Multi-Institutional Initiative to Engage Students and Early-Stage Scholars From Underrepresented Racial and Ethnic Minority Groups in HIV Research: The Centers for AIDS Research Diversity, Equity, and Inclusion Pathway Initiative

    by Manya Magnus, Lorena Segarra, Brandi Robinson, Kim Blankenship, Amy Corneli, Musie Ghebremichael, Nathan Irvin, Roger McIntosh, Kevin E. Favor, Kelly L. Jordan-Sciutto, et al.

    Background: The Centers for AIDS Research Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI) aims to establish programs to develop pathways for successful careers in HIV science among scholars from underrepresented racial and ethnic populations. This article describes cross-site evaluation outcomes during the first 18 months (July 2021–December 2022) across 15 programs. Methods: The aims of the evaluation were to characterize participants, describe feasibility, challenges, and successes of the programs and provide a basis for the generalizability of best practices to Diversity, Equity, and Inclusion (DEI) programs in the United States. Two primary data collection methods were used: a quarterly programmatic monitoring process and a centrally managed, individual-level, participant quantitative and qualitative survey. Results: During the first year of evaluation data collection, 1085 racially and ethnically diverse scholars ranging from the high school to postdoctoral levels applied for CDEIPI programs throughout the United States. Of these, 257 (23.7%) were selected to participate based on program capacity and applicant qualifications. Participants were trained by 149 mentors, teachers, and staff. Of the N = 95 participants responding to the individual-level survey, 95.7% agreed or strongly agreed with statements of satisfaction with the program, 96.8% planned to pursue further education, and 73.7% attributed increased interest in a variety of HIV science topics to the program. Qualitative findings suggest strong associations between mentorship, exposure to scientific content, and positive outcomes. Conclusions: These data provide evidence to support the feasibility and impact of novel DEI programs in HIV research to engage and encourage racially and ethnically diverse scholars to pursue careers in HIV science.


  • Open Access

    Using Health Care Professionals’ Perspectives to Refine a Clinical Decision Support Implementation Strategy for Increasing the Prescribing of HIV Preexposure Prophylaxis (PrEP) in Alabama

    by Debbie L. Humphries, Elizabeth C. Rhodes, Christine L. Simon, Victor Wang, Donna Spiegelman, Corilyn Ott, David Hicks, Julia L. Marcus, Doug Krakower, Aadia Rana

    Pre-exposure prophylaxis (PrEP) is underused in the southern United States (US), a region with high HIV incidence. Clinical decision support (CDS) tools could increase PrEP prescriptions. We explored barriers to PrEP delivery and views of CDS tools to identify refinements for implementation strategies for PrEP prescribing and PrEP CDS tools. We conducted focus groups with health care providers from two federally qualified health centers in Alabama and analyzed the results using rapid qualitative methods. Barriers to PrEP included providers’ lack of training in PrEP, competing priorities and time constraints during clinical visits, concerns about side effects, and intensive workload. We identified refinements to the planned implementation strategies to address the barriers, including training all clinic staff in PrEP and having CDS PrEP alerts in electronic health records sent to all staff. Development and deployment of CDS tools in collaboration with providers has potential to increase PrEP prescribing in high-priority jurisdictions.